Please login to the form below

Not currently logged in
Email:
Password:

Colobreathe

This page shows the latest Colobreathe news and features for those working in and with pharma, biotech and healthcare.

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use. Cystic fibrosis patients in England and Wales will now have access to two new drugs from Novartis and Forest Laboratories to treat ... The limited recommendation takes into account that the Tobi

Latest news

  • NICE backs two cystic fibrosis treatments for NHS use NICE backs two cystic fibrosis treatments for NHS use

    Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price. Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe have both received backing for use in the NHS in England and Wales ... NICE had previously ruled that there

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics